11C-PiB与124I抗体PET在治疗干预后对脑淀粉样β蛋白的评估存在差异
本研究在晚期Aβ病理的两种阿尔茨海默病小鼠模型中,比较了靶向非纤维型Aβ的抗体PET配体与11C-PiB在BACE-1抑制后的检测效果。结果显示抗体配体可检测治疗后的Aβ水平下降,而11C-PiB PET未能量化该变化,提示两种配体检测不同的Aβ池。
要点
- 抗体放射配体可检测BACE-1抑制剂治疗后脑Aβ水平下降。
- 11C-PiB PET未能显示NB-360治疗组与对照组的信号差异。
- 两种配体检测不同Aβ池,提示联合评估可能更全面。
核心结论
- 抗体放射配体可检测抗Aβ治疗后脑Aβ水平变化。
- 11C-PiB PET未能量化Aβ水平下降,提示配体检测不同Aβ池。
研究设计与样本
- 在晚期Aβ病理的ArcSwe和AppNL-G-F两种AD小鼠模型中比较抗体PET配体与11C-PiB。
- ArcSwe小鼠16月龄起用BACE-1抑制剂NB-360治疗2月,设同龄对照和16月龄基线组。
- AppNL-G-F小鼠8月龄起NB-360治疗,行11C-PiB PET和125I-RmAb158-scFv8D3 SPECT。
主要发现
- NB-360治疗的ArcSwe小鼠海马和丘脑124I-RmAb158-scFv8D3浓度与基线相似且显著低于同龄未治疗对照。
- NB-360治疗的AppNL-G-F小鼠海马、皮层和小脑125I-RmAb158-scFv8D3滞留降低。
- 放射配体在体浓度与死后脑组织可溶性Aβ聚集体分析对应。
- 两模型中NB-360治疗组11C-PiB信号与未治疗对照相比未降低,且NB-360和对照小鼠11C-PiB信号有高于基线组趋势但未达显著性。
临床怎么用
- 抗体PET配体或可用于监测抗Aβ治疗后的Aβ水平变化。
- 11C-PiB PET可能不适用于量化此类治疗引起的Aβ下降。
局限性
- 研究仅基于两种AD小鼠模型,尚未在人体验证。
- 11C-PiB信号高于基线的趋势未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PET imaging of amyloid-β (Aβ) has become an important component of Alzheimer disease diagnosis. 11C-Pittsburgh compound B (11C-PiB) and analogs bind to fibrillar Aβ. However, levels of nonfibrillar, soluble, aggregates of Aβ appear more dynamic during disease progression and more affected by Aβ-reducing treatments. The aim of this study was to compare an antibody-based PET ligand targeting nonfibrillar Aβ with 11C-PiB after β-secretase (BACE-1) inhibition in 2 Alzheimer disease mouse models at an advanced stage of Aβ pathology. Methods: Transgenic ArcSwe mice (16 mo old) were treated with the BACE-1 inhibitor NB-360 for 2 mo, whereas another group was kept as controls. A third group was analyzed at the age of 16 mo as a baseline. Mice were PET-scanned with 11C-PiB to measure Aβ plaque load followed by a scan with the bispecific radioligand 124I-RmAb158-scFv8D3 to investigate nonfibrillar aggregates of Aβ. The same study design was then applied to another mouse model, AppNL-G-F In this case, NB-360 treatment was initiated at the age of 8 mo and animals were scanned with 11C-PiB-PET and 125I-RmAb158-scFv8D3 SPECT. Brain tissue was isolated after scanning, and Aβ levels were assessed. Results: 124I-RmAb158-scFv8D3 concentrations measured with PET in hippocampus and thalamus of NB-360-treated ArcSwe mice were similar to those observed in baseline animals and significantly lower than concentrations observed in same-age untreated controls. Reduced 125I-RmAb158-scFv8D3 retention was also observed with SPECT in hippocampus, cortex, and cerebellum of NB-360-treated AppNL-G-F mice. Radioligand in vivo concentrations corresponded to postmortem brain tissue analysis of soluble Aβ aggregates. For both models, mice treated with NB-360 did not display a reduced 11C-PiB signal compared with untreated controls, and further, both NB-360 and control mice tended, although not reaching significance, to show higher 11C-PiB signal than the baseline groups. Conclusion: This study demonstrated the ability of an antibody-based radioligand to detect changes in brain Aβ levels after anti-Aβ therapy in ArcSwe and AppNL-G-F mice with pronounced Aβ pathology. In contrast, the decreased Aβ levels could not be quantified with 11C-PiB PET, suggesting that these ligands detect different pools of Aβ.
引用
- Meier SR, Sehlin D, Roshanbin S, et al. 11C-PiB and 124I-Antibody PET Provide Differing Estimates of Brain Amyloid-β After Therapeutic Intervention. J Nucl Med. 2021. PMID: 34088777. doi:10.2967/jnumed.121.262083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。